Genzyme Transgenics Securities Corp.

Synta Pharmaceuticals Announces Key Senior Additions to Business and Scientific Teams; - Appoints Robert Terifay, Senior Vice President, Commercial Development and Strategy and Additional Senior Executives -.
PR Newswire; 4/8/2005; 1470 words; ...Synta Pharmaceuticals Corp., a product-focused...commercial perspective at securities analysts and earnings...increasing responsibility at Genzyme Transgenics Corp/Mason Laboratories...Regulatory Affairs at Genzyme Corporation, where...

Genzyme folding Biosurgery shares into Genzyme General.
Medical Device Daily; 5/13/2003; 1190 words; ...Banc of America Securities (San Francisco...the stocks. For Genzyme General, it now...new additions to Genzyme General, the most...research note. Genzyme Corp. began housing...formed Genzyme Transgenics, then Genzyme...

GENZYME TO QUIT TRACKING STOCKS INVESTORS SAY MOVE UNDERVALUES A UNIT
The Boston Globe; 5/9/2003; 975 words; ...Henri A. Termeer, Genzyme's chief executive...bargain prices. "Genzyme Corp. is a $9 billion...institutional holder of Genzyme Biosurgery shares...Tracking stocks are securities created to monitor...stock, Genzyme Transgenics, in 1993. The...

ETC. . .
The Boston Globe; 5/3/2002; 258 words; Genzyme Transgenics Corp. of Framingham received a five-year, $11.6 million credit line in March, according to the company's quarterly report with the Securities and Exchange Commission. Of the total, $5.5 million was used...

Genzyme Transgenics Reports Third Quarter 2001 Financial Results.
Genomics & Genetics Weekly; 11/16/2001; 929 words; ...com & NewsRx.net) -- Genzyme Transgenics Corp. (GZTC) has reported financial...proceeds from the sale of Primedica Corp. to Charles River Laboratories...million in cash and marketable securities. GTC used $4 million of cash...